Inotuzumab Ozogamacin (1mg)
Inonza 1mg Injection is a CD22-directed antibody-drug conjugate (ADC) used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Injection
Inonza 1mg Injection is given as an injection into veins by the healthcare provider. The dose will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it the wrong way or in more than the recommended dose can cause very serious side effects. It may take several weeks or months to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Your doctor or nurse will give you this medicine. Kindly do not self-administer.
Decreased blood cells (red cells, white cells, and platelets) Infection Fatigue Hemorrhage Fever Nausea Headache Increased liver enzymes Abdominal pain
Avoid breastfeeding during the treatment and for two months after the last dose.
Inonza 1mg Injection contains Inotuzumab Ozogamicin, an antineoplastic agent that treats relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL) in adults. It targets CD22 antigen expressed on immature B-cell lymphocytes and blocks further growth of tumor cells.
Your doctor may monitor your blood counts and liver before you start taking Inonza 1mg Injection and regularly throughout your treatment. Males and females of reproductive potential should use effective contraception during the treatment and for at least five and eight months respectively after the last dose. Avoid breastfeeding during the treatment and for two months after the last dose. Inonza 1mg Injection can make you feel dizzy for the first few days. Rise slowly if you have been sitting or lying down for a long time. After starting the treatment with Inonza 1mg Injection, you may be at risk of infection; so try to avoid crowds or people with colds and report fever or any other signs of infection immediately to your doctor.